APA (7th ed.) Citation

Besse, B., Pons-Tostivint, E., Park, K., Hartl, S., Forde, P. M., Hochmair, M. J., . . . Heymach, J. V. (2024). Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: A phase 2 umbrella trial. Nature medicine, 30(3), . https://doi.org/10.1038/s41591-024-02808-y

Chicago Style (17th ed.) Citation

Besse, Benjamin, et al. "Biomarker-directed Targeted Therapy Plus Durvalumab in Advanced Non-small-cell Lung Cancer: A Phase 2 Umbrella Trial." Nature Medicine 30, no. 3 (2024). https://doi.org/10.1038/s41591-024-02808-y.

MLA (9th ed.) Citation

Besse, Benjamin, et al. "Biomarker-directed Targeted Therapy Plus Durvalumab in Advanced Non-small-cell Lung Cancer: A Phase 2 Umbrella Trial." Nature Medicine, vol. 30, no. 3, 2024, https://doi.org/10.1038/s41591-024-02808-y.